Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI7352 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

December 2, 2021

Study Completion Date

December 2, 2021

Conditions
Painful Osteoarthritis of the Knee
Interventions
DRUG

MEDI7352

A dose of MEDI7352 will be administered as two 1.5 mL injections in the abdomen. Following an overnight fast of at least 8 hours, each participant will receive a single dose of MEDI7352 on 4 occasions.

DRUG

Placebo

Matching placebo will be administered as two 1.5 mL injections in the abdomen. To maintain the double-blind requirements, the placebo volume administered will be equivalent to the MEDI7352 volume administered for each dosing. Following an overnight fast of at least 8 hours, each participant will receive matching placebo on 4 occasions.

Trial Locations (1)

HA1 3UJ

Research Site, Harrow

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY